Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Assets (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Current Assets for 13 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 20.61% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 20.61% year-over-year, with the annual reading at $1.2 billion for FY2025, 20.61% up from the prior year.
  • Current Assets for Q4 2025 was $1.2 billion at Madrigal Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • The five-year high for Current Assets was $1.3 billion in Q3 2025, with the low at $157.1 million in Q3 2022.
  • Average Current Assets over 5 years is $625.7 million, with a median of $346.3 million recorded in 2022.
  • The sharpest move saw Current Assets tumbled 48.14% in 2022, then skyrocketed 351.72% in 2024.
  • Over 5 years, Current Assets stood at $271.7 million in 2021, then surged by 33.01% to $361.4 million in 2022, then skyrocketed by 76.35% to $637.3 million in 2023, then soared by 62.08% to $1.0 billion in 2024, then rose by 20.61% to $1.2 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $1.2 billion, $1.3 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.